Birch Allergy Market

Market Overview:

The 7 major birch allergy markets reached a value of US$ 399.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 710.1 Million by 2034, exhibiting a growth rate (CAGR) of 5.38% during 2024-2034.

The birch allergy market has been comprehensively analyzed in IMARC's new report titled "Birch Allergy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Birch allergy is a common type of seasonal disease triggered by an individual's immune response to proteins found in birch tree pollen. Birch trees are prevalent in many regions, particularly in temperate climates, and their pollen becomes airborne during springtime, leading to allergic reactions in sensitive people. The symptoms of the ailment can range from mild to severe and typically manifest in the respiratory system and skin. Some common symptoms include sneezing, a runny or stuffy nose, itchy and watery eyes, nasal congestion, and throat irritation. In a few cases, individuals suffering from this illness may also experience skin rashes, hives, or eczema. Diagnosing a birch allergy involves a comprehensive evaluation by an allergist. The process often begins with a thorough medical history and a physical examination to assess the symptoms and potential triggers. Allergy testing, like skin prick tests or blood workups, is also recommended to identify the specific allergens responsible for the disease.

The increasing prevalence of various environmental factors, including climate change and poor air quality, which lead to extended pollen seasons and higher pollen concentrations, is primarily driving the birch allergy market. In addition to this, the rising incidence of inadequate or lack of immunization against specific allergens, resulting in an enhanced risk of developing allergic reactions, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective drugs, such as antihistamines, corticosteroids, leukotriene modifiers, etc., to manage the symptoms of the ailment by blocking the release or effects of histamines, inflammatory molecules, and leukotrienes, respectively, is further bolstering the market growth. Additionally, the rising usage of allergen immunotherapy, including subcutaneous and sublingual treatments, is also acting as another significant growth-inducing factor. This therapy works by gradually exposing patients to small amounts of the allergen, such as birch pollen, to desensitize their immune system and reduce the severity of allergic reactions over time. Furthermore, the emerging popularity of epinephrine auto-injectors, since they help to counteract the effects of allergens, restore normal breathing and heart rate, and provide immediate relief in severe disease conditions like anaphylaxis, is expected to drive the birch allergy market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the birch allergy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for birch allergy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the birch allergy market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the birch allergy market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the birch allergy market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current birch allergy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the birch allergy market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the birch allergy market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the birch allergy market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of birch allergy across the seven major markets?
• What is the number of prevalent cases (2018-2034) of birch allergy by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of birch allergy by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with birch allergy across the seven major markets?
• What is the size of the birch allergy patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of birch allergy?
• What will be the growth rate of patients across the seven major markets?
   

Birch Allergy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for birch allergy drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the birch allergy market?
• What are the key regulatory events related to the birch allergy market?
• What is the structure of clinical trial landscape by status related to the birch allergy market?
• What is the structure of clinical trial landscape by phase related to the birch allergy market?
• What is the structure of clinical trial landscape by route of administration related to the birch allergy market?